A phase II study of carboplatin and vinorelbine as second-line treatment for advanced breast cancer.

Forty-one patients with advanced breast cancer were given carboplatin and vinorelbine as second-line therapy. Overall objective response rate was 46% (95% confidence interval 26-56%). Myelotoxicity was the most frequently observed toxic effect; grade III-IV leucopenia occurred in 46% of the patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Iaffaioli, R. V., Tortoriello, A., Facchini, G., Santangelo, M., De Sena, G., Gesue, G., Bucci, L., Scaramellino, G., Anastasio, E., Finizio, A.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1995
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2033957/
https://www.ncbi.nlm.nih.gov/pubmed/7577478

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2033957/
https://www.ncbi.nlm.nih.gov/pubmed/7577478

Ejemplares similares